February 22, 2023
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn: | Jason Drory |
Re: | VectivBio Holding AG |
Registration Statement on Form F-3
Filed January 27, 2023
File No. 333-269450
Acceleration Request
Requested Date: February 24, 2023
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the Registrant) hereby requests that the Securities and Exchange Commission (the Commission) take appropriate action to cause the above-referenced Registration Statement on Form F-3 (File No. 333-269450) (the Registration Statement), to become effective on February 24, 2023, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the Commissions staff. The Registrant hereby authorizes Brandon Fenn of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Brandon Fenn of Cooley LLP at (212) 479-6626.
[Signature page follows]
Very truly yours, | ||
VectivBio Holding AG | ||
By: | /s/ Luca Santarelli | |
Luca Santarelli | ||
Chief Executive Officer |
cc: | Scott Applebaum, VectivBio Holding AG |
Brandon Fenn, Cooley LLP
Dayne Brown, Cooley LLP
Andreas Müller, Homburger AG